domingo, 13 de septiembre de 2026

When it comes to women’s health, money talks Market forces are driving the case to fund research and improve treatment By Elizabeth CooneyAug. 26, 2026

https://www.statnews.com/2026/08/26/womens-health-reverse-pitch-profit-driven-approach-endometriosis-osteoporosis/

The gifts from pharma companies that keep on giving Study finds doctors continue to embrace industry freebies over time, despite rancorous debate over the issue

https://www.statnews.com/pharmalot/2026/09/10/many-doctors-still-embrace-pharma-freebies-rely-on-sales-reps/ By Ed SilvermanSept. 10, 2026 Pharmalot Columnist, Senior Writer

Why two promising heart drugs flopped and what’s next By Adam Feuerstein, Elaine Chen, and Allison DeAngelisSept. 10, 2026

https://www.statnews.com/2026/09/10/readout-loud-podcast-heart-disease-drugs-failed-trials/ By Adam Feuerstein, Elaine Chen, and Allison DeAngelisSept. 10, 2026

Platinum-based chemotherapy in childhood causes mutations that age the liver Study shows need for lifelong monitoring for potential cancers, authors say

https://www.statnews.com/2026/09/10/childhood-chemotherapy-cisplatin-carboplatin-new-study-liver-impact/ By Annalisa MerelliSept. 10, 2026 Contributing Writer

An AI tool aims to catch harder-to-detect heart attacks in EKGs FDA authorizes Powerful Medical’s Queen of Hearts algorithm to help triage heart attacks

https://www.statnews.com/2026/09/11/fda-new-ekg-heart-attack-detection-algo-queen-of-hearts/ By Katie PalmerSept. 11, 2026 Health Tech Correspondent

Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field Expert says that after resurgence in cardiovascular trials, investments will be harder to come by

https://www.statnews.com/2026/09/11/novartis-novo-nordisk-cardiovascular-drug-trials-fallout/ By Allison DeAngelis and Adam FeuersteinSept. 11, 2026 Adam Feuerstein adam.feuerstein@statnews.com Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

I’m a public health communications consultant. Pro-vaccine advocacy needs more fun Vaccines are something to celebrate By Adam ZimmermanSept. 11, 2026 Zimmerman is a public health communications consultant.

https://www.statnews.com/2026/09/11/pro-vaccine-advocacy-celebration-party/